Objective To investigate the risk factors and predictors of poor outcome in full-term neonates with severe hyperbilirubinemia. Methods Data were retrospectively collected from 326 neonates with severe hyperbilirubinemia hospitalized between January 1, 2012 and December 31, 2012. Results A total of 326 full-term neonates with severe hyperbilirubinemia were included in this study (181 males and 145 females). The average gestational age was 39.12±1.17 weeks. Two hundred and sixty (260) cases were followed up successfully by phone while 66 cases were lost to follow-up. Infection (74.40%) and hemolytic disease (51.19%) were the main causes of severe hyperbilirubinemia. Multiple factors regression analysis found that threshold TSB was an independent risk factor of poor outcome (OR=2.02, 95%CI:1.13~3.62, P=0.018). The outcome of neonates with BIND scored between 0-6 had poor prognosis and some of them were reversible, and the outcome in those scored between 7-9 were of worse prognosis. Threshold TSB, USB and B/A ratio in group of poor outcome were signiifcantly higher than those in other groups and their area under the ROC curve evaluating the prognosis was 0.682, 0.671 and 0.698, respectively. With TSB at 474.5 μmol/L, UCB at 449.15 μmol/L and B/A at 0.923 mg/g, Youden index was the higest. The results of BAEP, OSE, MRI and NBNA were not signiifcantly different between groups with or without poor outcome. Conclusions Threshold TSB is an independent risk factor of poor outcome in full-term newborns with severe hyperbilirubinemia. BIND score is a very good predictor of outcome. TSB threshold, USB and B/A ratio are the predictors of outcome, but their diagnostic values are limited. NBNA, hearing screening and hyperintense globus pallidus on T1W1 in the acute phase of jaundice might not related with neurologic prognosis.

Objective: To discuss the clinical significance of plasma von Willebrand factor (vWF), vascular endothelial growth factor (VEGF), and matrix metalloproteinase-9 (MMP-9) in patients with cerebral infarction in the process of occurrence and development of cerebral infarction. Methods: Thirty patients with cerebral infarction were divided into 3 groups according to their size of infarction: large infarction, moderate infarction, and small infarction (ten patients in each group). Enzyme-linked immunoadsordent assay (ELISA) was used to detect the concentrations of plasma vWF, VEGF, and MMP-9 in patient with cerebral infarction and in 20 healthy controls on day 1, 3, 7, and 15. Results: The mean levels of vWF (216 ± 62) μg/L, VEGF (584 ± 151) ng/ L, and MMP-9 (287 ± 147) μg/L in the cerebral infarction groups were significantly higher than those in the control group [vWF (96 ± 12) μg/ L, VEGF (111 ± 17) ng /L, and MMP-9 (102 ± 14) μg/L; P < 0.01]. The changes of plasma concentrations of the above 3 factors were correlated positively with the volume of cerebral infarction at the same time point in early cerebral infarction (r = 0.496, r = 0.519, r = 0.472 respectively; all P < 0.01). Conclusion: The concentrations of plasma vWF, VEGF, and MMP-9 were associated with the volume of cerebral infarction.

Accidents, Occupational ; Acrylamide ; poisoning ; Adolescent ; Critical Illness ; Humans ; Male ; Young Adult

Adult ; Aged ; Benzidines ; toxicity ; Coloring Agents ; Humans ; Male ; Middle Aged ; Occupational Exposure ; Urinary Bladder Neoplasms ; epidemiology

This article was a perspective study on natural pigment's new microbial resources,culture conditions,fermentation processes and genetic engineering strains,which provides some future direction for the development and application of natural pigment.

Adult ; Ethylene Glycol ; poisoning ; Female ; Humans ; Male ; Middle Aged ; Young Adult

Objective: To examine the expression of Nrf2 (nuclear factor erythroid 2-related factor 2) protein in patients with NSCLC (advanced non-small cell lung cancer), and to elucidate the correlation of the expression level of Nrf2 with response to platinum-based first-line chemotherapy and the prognosis of NSCLC patients. Methods: This retrospective study enrolled 50 patients with chemotherapynaïve advanced NSCLC. All patients received platinum-based regimens as first-line chemotherapy. The expression level of Nrf2 protein in tumor specimens was detected by immunohistochemical analysis. The associations between Nrf2 expression with response to chemotherapy and the prognosis were analyzed by SPSS 17.0 statistical software. Results: The Nrf2 protein expression level in NSCLC patients exhibited interindividual differences and the positive rate was 34% (17/50). The positive-expression rate of Nrf2 was higher in patients with age ≥ 70 years (58.3%, 7/12) than that in patients with age < 70 years (26.3%, 10/38) (P = 0.041), which was also higher in patients with distant metastasis (46.7%, 14/30) than that in patients without metastasis (15.0%, 3/20) (P = 0.021). The expression of Nrf2 was correlated with age (r = 0.370, P = 0.020), distant metastasis (r = 0.289, P = 0.042), response to platinum-based chemotherapy (r = 0.315 P = 0.026), progression-free survival (r = -0.393, P = 0.006) and overall survival (r = -0.309, P = 0.029). Furthermore, the expression of Nrf2 was an independent predictive factor for response to platinum-based first-line chemotherapy and progression-free survival (P < 0.05). Conclusion: Nrf2 expression is an independent predictor of response to platinum-based first-line chemotherapy and the prognosis of patients with advanced NSCLC, and it may be helpful to select the appropriate chemotherapy regimen for advanced NSCLC. Copyright © 2012 by TUMOR.

Objective: To investigate the interindividual variation of nuclear factor erythroid 2-related factor 2 (Nrf2) mRNA expression level in the peripheral blood nucleated cells and its correlation with the severity of chemotherapy-induced myelosuppression. Methods: The expression level of Nrf2 mRNA in the peripheral blood nucleated cells from 30 cases of cancer was detected by semi-quantitative RT-PCR before chemotherapy, and the association between the Nrf2 mRNA expression and the chemotherapyinduced myelosuppression was analyzed. Results: The Nrf2 mRNA expression level in the peripheral blood mononuclear cells exhibited significant interindividual differences. The Nrf2 mRNA expression level was significantly higher in the patients with grades 0-1 leukopenia or neutropenia than that in the patients with grades 2-4 (P <0.05), but it was not associated with the age, gender, chemotherapeutic regimen and the type of tumor. The association analysis showed that the Nrf2 mRNA expression level in the peripheral blood mononuclear cells was negatively associated with leukopenia and neutropenia (r = -0.448, P = 0.013; r = -0.493, P = 0.006). Conclusion: The expression level of Nrf2 mRNA in the peripheral blood mononuclear cells is significantly correlated with chemotherapy-induced myelosuppression. It may be employed as an ideal marker to predict the severity of chemotherapy-induced myelosuppression and helpful for clinical decision-making and early prevention and treatment of myelosuppression. Copyright © 2012 by TUMOR.

Post-traumatic stress disorder (PTSD) has long been clinical practice to use a three-part phased model in the treatment of trauma and the dissociative disorders. The phased treatment is an intrinsic element of the model presented throughout this article, which integrates the eye movement desensitization and reprocessing (EMDR) standard protocol and additional components: ego state therapy, attachment theory, and dissociative disorder treatment interventions. Although the researches on this model are still in its infancy, it is the current standard of care because of its efficacy with traumatized and dissociative-disordered clients.

It is necessary to improve the level of the inter-disciplinary teamwork,since the intellectual disability are living in a complicated circumstances.When the policy makers are working,they should consider the suggestion of psychologists and the situation that the service users and their relatives are facing.It is also important and practical for us to provide the assessment to the disability capacity to consent and decide.